VivoSeq
Infectious Disease

Bacterial Endocarditis

1

Pipeline Programs↗

0

Active Trials↗

0

Companies Involved↗

Bacterial Endocarditis is an early-stage landscape with 1 program across 0 companies. 1 therapy is approved.

Intelligence

Pipeline Metrics

Competitive Density

10/100

Pipeline Velocity

0/100

Mech. Concentration

N/A

Completion Rate

N/A

Attrition Rate

N/A

Pipeline

Programs by Phase

Preclinical
No programs
Phase 1
No programs
Phase 2
No programs
Phase 3
No programs
Approved1

Daptomycin

Baxter Healthcare Corporation

Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)